Business Context and Reporting Period
This Form 8-K reports on the 2013 Annual Meeting of Stockholders held by Oculus Innovative Sciences, Inc. on September 12, 2013. The filing details the voting results for director elections, executive compensation advisory votes, and the ratification of the independent auditor. Note: The request metadata references "Sonoma Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as "Oculus Innovative Sciences, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders with the following outcomes:
- Shareholder Participation: Of 6,625,555 shares entitled to vote, 4,394,827 shares were present or represented by proxy.
- Proposal 1 (Election of Class II Directors): Jay Birnbaum and Jim Schutz were elected.
- Jay Birnbaum: 1,059,810 votes FOR; 123,407 votes WITHHELD.
- Jim Schutz: 1,048,103 votes FOR; 135,114 votes WITHHELD.
- Proposal 2 (Advisory Vote on Executive Compensation): Approved.
- FOR: 927,758
- AGAINST: 217,623
- ABSTAIN: 37,836
- Proposal 3 (Frequency of Compensation Votes): Stockholders voted for an annual frequency.
- ONE YEAR: 609,014 votes
- THREE YEARS: 502,389 votes
- TWO YEARS: 54,395 votes
- ABSTAIN: 17,419 votes
Consequently, the Board determined to conduct future advisory votes on an annual basis.
- Proposal 4 (Ratification of Auditor): Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2014.
- FOR: 4,052,281
- AGAINST: 198,018
- ABSTAIN: 144,528
- BROKER NON-VOTES: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, specific risks, contingencies, or unusual items. The only forward-looking determination noted is the Board's decision to hold annual executive compensation advisory votes based on the shareholder vote results.
Important Facts for Investors to Verify
- Confirm the registrant name is Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc.
- Verify the election of Jay Birnbaum and Jim Schutz as Class II directors serving until 2016.
- Note the shareholder preference for annual executive compensation advisory votes.
- Confirm the appointment of Marcum LLP as the independent auditor for the fiscal year ending March 31, 2014.
- Review the July 29, 2013 proxy statement for detailed background on the proposals and executive compensation figures.